These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36208918)

  • 1. Neuroactive steroids - new possibilities in the treatment of postpartum depression.
    Žigová L; Massarová P; Vranecová K; Hrubá O; Adamičková A; Gažová A
    Ceska Slov Farm; 2022; 71(4):142-150. PubMed ID: 36208918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy of Postpartum Depression: Current Approaches and Novel Drug Development.
    Frieder A; Fersh M; Hainline R; Deligiannidis KM
    CNS Drugs; 2019 Mar; 33(3):265-282. PubMed ID: 30790145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on approved and emerging drugs for the treatment of postpartum depression.
    Çulcu EA; Demiryürek Ş; Demiryürek AT
    Ideggyogy Sz; 2024 Jul; 77(7-8):227-235. PubMed ID: 39082257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [GABAergic approach of postpartum depression: A translational review of literature].
    Verbe J; Dubertret C; El-Hage W; Bonnet-Brilhault F; Duriez P
    Encephale; 2020 Apr; 46(2):123-134. PubMed ID: 31767256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical pharmacology of brexanolone (allopregnanolone) for postpartum depression: a landmark journey from concept to clinic in neurosteroid replacement therapy.
    Reddy DS; Mbilinyi RH; Estes E
    Psychopharmacology (Berl); 2023 Sep; 240(9):1841-1863. PubMed ID: 37566239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
    Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ
    Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of neuroactive steroids for the treatment of postpartum depression.
    Gunduz-Bruce H; Takahashi K; Huang MY
    J Neuroendocrinol; 2022 Feb; 34(2):e13019. PubMed ID: 34462985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of Allopregnanolone Agonist Therapy for the Treatment of Depressive Disorders.
    Walkery A; Leader LD; Cooke E; VandenBerg A
    Drug Des Devel Ther; 2021; 15():3017-3026. PubMed ID: 34267503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating brexanolone for the treatment of postpartum depression.
    Payne JL
    Expert Opin Pharmacother; 2021 Jun; 22(8):959-964. PubMed ID: 33645386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
    Meltzer-Brody S; Colquhoun H; Riesenberg R; Epperson CN; Deligiannidis KM; Rubinow DR; Li H; Sankoh AJ; Clemson C; Schacterle A; Jonas J; Kanes S
    Lancet; 2018 Sep; 392(10152):1058-1070. PubMed ID: 30177236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexanolone to Treat Postpartum Depression in Adult Women.
    Cornett EM; Rando L; Labbé AM; Perkins W; Kaye AM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2021 Mar; 51(2):115-130. PubMed ID: 34092826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zuranolone - synthetic neurosteroid in treatment of mental disorders: narrative review.
    Marecki R; Kałuska J; Kolanek A; Hakało D; Waszkiewicz N
    Front Psychiatry; 2023; 14():1298359. PubMed ID: 38116383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression.
    Carlini SV; Osborne LM; Deligiannidis KM
    Dialogues Clin Neurosci; 2023 Dec; 25(1):92-100. PubMed ID: 37796239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexanolone for the treatment of patients with postpartum depression.
    Morrison KE; Cole AB; Thompson SM; Bale TL
    Drugs Today (Barc); 2019 Sep; 55(9):537-544. PubMed ID: 31584571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience.
    Lüscher B; Möhler H
    F1000Res; 2019; 8():. PubMed ID: 31275559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zuranolone, a neuroactive drug, used in the treatment of postpartum depression by modulation of GABA
    Sharma R; Bansal P; Saini L; Sharma N; Dhingra R
    Pharmacol Biochem Behav; 2024 May; 238():173734. PubMed ID: 38387651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.
    Kanes SJ; Colquhoun H; Doherty J; Raines S; Hoffmann E; Rubinow DR; Meltzer-Brody S
    Hum Psychopharmacol; 2017 Mar; 32(2):. PubMed ID: 28370307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexanolone for postpartum depression.
    Hutcherson TC; Cieri-Hutcherson NE; Gosciak MF
    Am J Health Syst Pharm; 2020 Feb; 77(5):336-345. PubMed ID: 32073124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brexanolone: A Novel Drug for the Treatment of Postpartum Depression.
    Patatanian E; Nguyen DR
    J Pharm Pract; 2022 Jun; 35(3):431-436. PubMed ID: 33302791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine insights into neurosteroid therapy for postpartum depression.
    Reddy DS
    Trends Mol Med; 2023 Dec; 29(12):979-982. PubMed ID: 37541828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.